Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B, Lungu E, Mitera G, Potashnik T, Reiman A, Ritcher T, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group.
Dai WF, et al. Among authors: boehm d.
Curr Oncol. 2021 Oct 16;28(5):4174-4183. doi: 10.3390/curroncol28050354.
Curr Oncol. 2021.
PMID: 34677272
Free PMC article.